Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
Cyclacel’s
ALIGN Pharmaceuticals subsidiary markets directly in the U.S.
Xclair™ Cream for radiation dermatitis,
Numoisyn™ Liquid and
Numoisyn™ Lozenges for xerostomia.
Applying its core strength in cell cycle biology, Cyclacel is advancing a pipeline of small molecule drugs designed to stop uncontrolled cell division. The Company has three clinical-stage compounds and a deep pipeline.
![Jump to content [Access key 'm']](/siteware/cleardot.gif){kind=small}
